The renaissance of corticotropin therapy in proteinuric nephropathies

Nature Reviews Nephrology

Volumn 8, Issue 2, 2012, Pages 122-128

  Gong, Rujun ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORAMBUCIL; CHOLESTEROL; CLUSTERIN; CORTICOTROPIN; CREATININE; CYCLOPHOSPHAMIDE; GLUCOCORTICOID; GUANINE NUCLEOTIDE BINDING PROTEIN; HYDROCORTISONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERMEDIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MELANOCORTIN; MELANOCORTIN 1 RECEPTOR; MELANOCORTIN 2 RECEPTOR; MELANOCORTIN 3 RECEPTOR; MELANOCORTIN 4 RECEPTOR; MELANOCORTIN 5 RECEPTOR; METHYLPREDNISOLONE; TETRACOSACTIDE;

ACUTE KIDNEY FAILURE; CHILDHOOD DISEASE; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; FOCAL GLOMERULOSCLEROSIS; FOLLOW UP; GLOMERULOSCLEROSIS; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOPHYSIS ADRENAL SYSTEM; KIDNEY DISEASE; KIDNEY FUNCTION; MEMBRANOUS GLOMERULONEPHRITIS; NEPHRITIS; NEPHROTIC SYNDROME; NONHUMAN; OPTIMAL DRUG DOSE; OSTEOLYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; PROTEINURIA; PROTEINURIC NEPHROPATHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL PROTECTION; REVIEW; SIDE EFFECT; SKIN PIGMENTATION; TREATMENT DURATION; TREATMENT RESPONSE; WEIGHT GAIN;

ADRENOCORTICOTROPIC HORMONE; ANIMALS; HORMONES; HUMANS; NEPHROTIC SYNDROME; PROTEINURIA; TREATMENT OUTCOME;

EID: 84856509510     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2011.190     Document Type: Review

References (62)

1. Dores, R. M. Adrenocorticotropic hormone, melanocyte-stimulating hormone, and the melanocortin receptors: revisiting the work of Robert Schwyzer: a thirty-year retrospective. Ann. NY Acad. Sci. 1163, 93-100 (2009).
2. Arneil, G. C. & Wilson, H. E. A.C.T.H. in nephrosis. Arch. Dis. Child. 28, 372-380 (1953).
3. Piel, C. F. Management of nephrosis; the use of long continued hormone therapy. Calif. Med. 85, 152-156 (1956).
4. Lauson, H. D., Forman, C. W., Mc, N. H., Mattar, G. & Barnett, H. L. The effect of corticotropin (ACTH) on glomerular permeability to albumin in children with the nephrotic syndrome. J. Clin. Invest. 33, 657-664 (1954).
5. Berg, A. L. & Arnadottir, M. ACTH revisited-potential implications for patients with renal disease. Nephrol. Dial. Transplant. 15, 940-942 (2000). (Pubitemid 30410360)
6. Ponticelli, C. Membranous nephropathy. J. Nephrol. 20, 268-287 (2007). (Pubitemid 47570357)
7. Cone, R. D. Studies on the physiological functions of the melanocortin system. Endocr. Rev. 27, 736-749 (2006). (Pubitemid 44936057)
8. Voisey, J., Carroll, L. & van Daal, A. Melanocortins and their receptors and antagonists. Curr. Drug Targets 4, 586-597 (2003). (Pubitemid 37139051)
9. Penhoat, A., Naville, D. & Begeot, M. The adrenocorticotropic hormone receptor. Curr. Opin. Endocrinol. Diabetes 8, 112-117 (2001). (Pubitemid 32476723)
10. Lindskog, A. et al. Melanocortin 1 receptor agonists reduce proteinuria. J. Am. Soc. Nephrol. 21, 1290-1298 (2010).
11. Gong, R. & Dworkin, L. D. ACTH (Acthar Gel) prevents proteinuria and renal injury in the remnant kidney: Evidence for direct podocyte protection. J. Am. Soc. Nephrol. 21, 548A (2010).
12. Chhajlani, V. Distribution of cDNA for melanocortin receptor subtypes in human tissues. Biochem. Mol. Biol. Int. 38, 73-80 (1996). (Pubitemid 26340463)
13. Sanchez, E., Rubio, V. C. & Cerda-Reverter, J. M. Characterization of the sea bass melanocortin 5 receptor: a putative role in hepatic lipid metabolism. J. Exp. Biol. 212, 3901-3910 (2009).
14. Ni, X. P., Bhargava, A., Pearce, D. & Humphreys, M. H. Modulation by dietary sodium intake of melanocortin 3 receptor mRNA and protein abundance in the rat kidney. Am. J. Physiol. Regul. Integr. Comp. Physiol. 290, R560-R567 (2006).
15. Lee, Y. S., Park, J. J. & Chung, K. Y. Change of melanocortin receptor expression in rat kidney ischemia-reperfusion injury. Transplant. Proc. 40, 2142-2144 (2008).
16. Schwandt, P. & Richter, W. O. Effects of pituitary peptides on fat mobilisation. Int. J. Obes. 6 (Suppl. 1), 49-54 (1982). (Pubitemid 12064622)
17. Berg, A. L., Hansson, P. & Nilsson-Ehle, P. ACTH 1-24 decreases hepatic lipase activities and low density lipoprotein concentrations in healthy men. J. Intern. Med. 229, 201-203 (1991).
18. Berg, A. L. & Nilsson-Ehle, P. ACTH lowers serum lipids in steroid-treated hyperlipemic patients with kidney disease. Kidney Int. 50, 538-542 (1996). (Pubitemid 26274382)
19. Beloff-Chain, A., Morton, J., Dunmore, S., Taylor, G. W. & Morris, H. R. Evidence that the insulin secretagogue, beta-cell-tropin, is ACTH22-39. Nature 301, 255-258 (1983). (Pubitemid 13142228)
20. Schoneshofer, M. & Goverde, H. J. Corticotropin in human plasma. General considerations. Surv. Immunol. Res. 3, 55-63 (1984).
21. Wan, L., Chen, Y. H. & Chang, T. W. Improving pharmacokinetic properties of adrenocorticotropin by site-specific lipid modification. J. Pharm. Sci. 92, 1882-1892 (2003). (Pubitemid 37071820)
22. Kohda, Y., Chiao, H. & Star, R. A. alpha-Melanocyte-stimulating hormone and acute renal failure. Curr. Opin. Nephrol. Hypertens. 7, 413-417 (1998). (Pubitemid 28341754)
23. Chiao, H. et al. Alpha-melanocyte-stimulating hormone protects against renal injury after ischemia in mice and rats. J. Clin. Invest. 99, 1165-1172 (1997). (Pubitemid 27142751)
24. Kolgazi, M., Arbak, S. & Alican, I. The effect of alpha-melanocyte stimulating hormone on gentamicin-induced acute nephrotoxicity in rats. J. Appl. Toxicol. 27, 183-188 (2007). (Pubitemid 46480586)
25. Li, C. et al. alpha-MSH prevents impairment in renal function and dysregulation of AQPs and Na-K-ATPase in rats with bilateral ureteral obstruction. Am. J. Physiol. Renal. Physiol. 290, F384-F396 (2006). (Pubitemid 43724992)
26. Gong, R., Ge, Y., Tolbert, E. M., Zhuang, S. & Dworkin, L. D. Renoprotection by adrenocorticotropin in experimental acute kidney injury. J. Am. Soc. Nephrol. 20, 510A (2009).
27. Garcia, D. L., Rennke, H. G., Brenner, B. M. & Anderson, S. Chronic glucocorticoid therapy amplifies glomerular injury in rats with renal ablation. J. Clin. Invest. 80, 867-874 (1987). (Pubitemid 18003961)
28. Berg, A. L. & Arnadottir, M. ACTH-induced improvement in the nephrotic syndrome in patients with a variety of diagnoses. Nephrol. Dial. Transplant. 19, 1305-1307 (2004). (Pubitemid 38628157)
29. Berg, A. L., Nilsson-Ehle, P. & Arnadottir, M. Beneficial effects of ACTH on the serum lipoprotein profile and glomerular function in patients with membranous nephropathy. Kidney Int. 56, 1534-1543 (1999). (Pubitemid 29451260)
30. Ponticelli, C. et al. A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy. Am. J. Kidney Dis. 47, 233-240 (2006). (Pubitemid 43121326)
31. Rauen, T., Michaelis, A., Floege, J. & Mertens, P. R. Case series of idiopathic membranous nephropathy with long-term beneficial effects of ACTH peptide 1-24. Clin. Nephrol. 71, 637-642 (2009).
32. Picardi, L. et al. ACTH therapy in nephrotic syndrome induced by idiopathic membranous nephropathy. Clin. Nephrol. 62, 403-404 (2004). (Pubitemid 39480853)
33. Bomback, A. S. et al. Treatment of resistant nephrotic syndrome with adrenocorticotropic hormone (ACTH) gel. Drug Des. Develop. Ther. 5, 147-153 (2011).
34. Beck, L. H. et al. Treatment of idiopathic membranous nephropathy with ACTH is associated with a decline in anti-PLA2R antibody. J. Am. Soc. Nephrol. 20, 306A (2009).
35. Beck, L. H. Jr et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N. Engl. J. Med. 361, 11-21 (2009).
36. Rosenblum, A. H. & Rosenblum, P. Anaphylactic reactions to adrenocorticotropic hormone in children. J. Pediatr. 64, 387-395 (1964).
37. Glassock, R. J. The treatment of idiopathic membranous nephropathy: a dilemma or a conundrum? Am. J. Kidney Dis. 44, 562-566 (2004). (Pubitemid 39164634)
38. Catania, A. The melanocortin system in leukocyte biology. J. Leukoc. Biol. 81, 383-392 (2007). (Pubitemid 46198388)
39. Symmers, W. S. Thrombotic microangiopathic haemolytic anaemia (thrombotic microangiopathy). Br. Med. J. 2, 897-903 (1952).
40. Catania, A., Gatti, S., Colombo, G. & Lipton, J. M. Targeting melanocortin receptors as a novel strategy to control inflammation. Pharmacol. Rev. 56, 1-29 (2004). (Pubitemid 38314578)
41. Remuzzi, G. & Bertani, T. Pathophysiology of progressive nephropathies. N. Engl. J. Med. 339, 1448-1456 (1998). (Pubitemid 28516069)
42. Johnson, E. W., Blalock, J. E. & Smith, E. M. ACTH receptor-mediated induction of leukocyte cyclic AMP. Biochem. Biophys. Res. Comm. 157, 1205-1211 (1988). (Pubitemid 19025985)
43. Lepique, A. P. et al. c-Myc protein is stabilized by fibroblast growth factor 2 and destabilized by ACTH to control cell cycle in mouse Y1 adrenocortical cells. J. Mol. Endocrinol. 33, 623-638 (2004). (Pubitemid 40057558)
44. Wang, H., Jia, Z., Liu, G. & Yang, T. Adrenocorticotropic hormone attenuates diabetic nephropathy in Zucker diabetic fatty rats via inhibition of oxidative and inflammatory response. J. Am. Soc. Nephrol. 21, 825A (2010).
45. Roth, J. A., Kaeberle, M. L. & Hsu, W. H. Effects of ACTH administration on bovine polymorphonuclear leukocyte function and lymphocyte blastogenesis. Am. J. Vet. Res. 43, 412-416 (1982). (Pubitemid 12101081)
46. Smith, E., Hammarstrom, L., Moller, E. & Matell, G. The effect of ACTH treatment on lymphocyte subpopulations in patients with myasthenia gravis. Neurology 26, 915-918 (1976).
47. Cooper, A. et al. Alpha-melanocyte-stimulating hormone suppresses antigen-induced lymphocyte proliferation in humans independently of melanocortin 1 receptor gene status. J. Immunol. 175, 4806-4813 (2005). (Pubitemid 41362024)
48. Andersen, G. N. et al. Quantitative measurement of the levels of melanocortin receptor subtype 1, 2, 3 and 5 and pro-opio-melanocortin peptide gene expression in subsets of human peripheral blood leucocytes. Scand. J. Immunol. 61, 279-284 (2005). (Pubitemid 40462779)
49. Gonzalez-Rey, E., Chorny, A. & Delgado, M. Regulation of immune tolerance by anti-inflammatory neuropeptides. Nat. Rev. Immunol. 7, 52-63 (2007). (Pubitemid 46020827)
50. Koyama, A., Fujisaki, M., Kobayashi, M., Igarashi, M. & Narita, M. A glomerular permeability factor produced by human T cell hybridomas. Kidney Int. 40, 453-460 (1991).
51. Tracey, K. J. The inflammatory reflex. Nature 420, 853-859 (2002). (Pubitemid 36019638)
52. Yeboah, M. M. et al. Cholinergic agonists attenuate renal ischemia-reperfusion injury in rats. Kidney Int. 74, 62-69 (2008). (Pubitemid 351841900)
53. Guarini, S. et al. Adrenocorticotropin reverses hemorrhagic shock in anesthetized rats through the rapid activation of a vagal anti-inflammatory pathway. Cardiovasc. Res. 63, 357-365 (2004). (Pubitemid 38900850)
54. Cases, A. & Coll, E. Dyslipidemia and the progression of renal disease in chronic renal failure patients. Kidney Int. Suppl. 68, S87-S93 (2005).
55. Rayner, B. L., Byrne, M. J. & van Zyl Smit, R. A prospective clinical trial comparing the treatment of idiopathic membranous nephropathy and nephrotic syndrome with simvastatin and diet, versus diet alone. Clin. Nephrol. 46, 219-224 (1996). (Pubitemid 26385555)
56. Rabelink, A. J., Hene, R. J., Erkelens, D. W., Joles, J. A. & Koomans, H. A. Partial remission of nephrotic syndrome in patient on long-term simvastatin. Lancet 335, 1045-1046 (1990). (Pubitemid 20148643)
57. Thomas, M. E. et al. Simvastatin therapy for hypercholesterolemic patients with nephrotic syndrome or significant proteinuria. Kidney Int. 44, 1124-1129 (1993). (Pubitemid 23316484)
58. Chan, P. C. et al. Lovastatin in glomerulonephritis patients with hyperlipidaemia and heavy proteinuria. Nephrol. Dial. Transplant. 7, 93-99 (1992).
59. Ghiggeri, G. M. et al. Depletion of clusterin in renal diseases causing nephrotic syndrome. Kidney Int. 62, 2184-2194 (2002). (Pubitemid 35366174)
60. Candiano, G. et al. Apolipoproteins prevent glomerular albumin permeability induced in vitro by serum from patients with focal segmental glomerulosclerosis. J. Am. Soc. Nephrol. 12, 143-150 (2001). (Pubitemid 32056799)
61. Berg, A. L. & Nilsson-Ehle, P. Direct effects of corticotropin on plasma lipoprotein metabolism in man-studies in vivo and in vitro. Metabolism 43, 90-97 (1994). (Pubitemid 24047110)
62. Rastaldi, M. P. et al. Glomerular clusterin is associated with PKC-alpha/beta regulation and good outcome of membranous glomerulonephritis in humans. Kidney Int. 70, 477-485 (2006). (Pubitemid 44141574)